Zimmer Biomet (NYSE:ZBH) Hits New 12-Month Low – Should You Sell?

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) shares hit a new 52-week low on Wednesday . The stock traded as low as $81.35 and last traded at $82.9540, with a volume of 9823679 shares trading hands. The stock had previously closed at $92.59.

Zimmer Biomet News Roundup

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q1 results beat expectations — adjusted EPS $2.09 vs. $1.86 estimate and revenue $2.09B, with reported sales up ~9.3% year-over-year and margin expansion, showing underlying business strength. Zimmer Biomet Announces First Quarter 2026 Financial Results
• Positive Sentiment: Company raised FY-2026 adjusted EPS guidance to $8.40–$8.55 (slightly above consensus) and reiterated revenue targets, supporting forward earnings outlook. Medical device maker Zimmer Biomet raises annual profit forecast, announces CFO departure
• Neutral Sentiment: Analyst write-ups highlight strong segment growth, solid organic sales and improved key metrics, but note mixed pre-market reaction (shares dipped despite the beat), indicating some investor profit-taking or concern about near-term execution. ZBH Q1 Earnings & Revenues Top Estimates, Stock Dips in Pre-Market
• Negative Sentiment: Chief Financial Officer Suketu Upadhyay departed effective April 28; an interim CFO was named. Management turnover in the finance role is creating uncertainty and likely weighing on the stock. Zimmer Biomet Announces Chief Financial Officer Transition
• Negative Sentiment: Reports of a CEO exit were published alongside the earnings release; headlines about executive departures and the company’s underperformance versus peers amplified investor concern and contributed to the selloff. Zimmer Biomet falls after CEO exit, unchanged growth outlook

Wall Street Analysts Forecast Growth

ZBH has been the topic of several recent analyst reports. Sanford C. Bernstein increased their target price on shares of Zimmer Biomet from $97.00 to $99.00 and gave the company a “market perform” rating in a research note on Friday, January 9th. UBS Group reissued a “sell” rating and issued a $89.00 target price on shares of Zimmer Biomet in a research note on Wednesday, February 11th. Citigroup reissued a “buy” rating on shares of Zimmer Biomet in a research note on Wednesday, February 11th. Weiss Ratings raised shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, April 7th. Finally, Barclays reduced their target price on shares of Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating on the stock in a research note on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $105.95.

Zimmer Biomet Stock Down 10.4%

The company has a market cap of $16.06 billion, a PE ratio of 23.43, a P/E/G ratio of 1.89 and a beta of 0.61. The company’s 50 day moving average is $93.23 and its 200 day moving average is $92.89. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping the consensus estimate of $1.86 by $0.23. The company had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The firm’s revenue was up 9.3% compared to the same quarter last year. During the same quarter last year, the firm posted $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.39 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is currently 27.12%.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 2,650 shares of the firm’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the transaction, the senior vice president owned 10,224 shares of the company’s stock, valued at $967,803.84. This trade represents a 20.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.28% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ZBH. Brighton Jones LLC purchased a new position in Zimmer Biomet in the 4th quarter worth about $204,000. Sivia Capital Partners LLC purchased a new position in Zimmer Biomet in the 2nd quarter worth about $232,000. United Bank increased its stake in Zimmer Biomet by 10.7% in the 2nd quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock worth $1,085,000 after buying an additional 1,153 shares during the period. Federated Hermes Inc. increased its stake in Zimmer Biomet by 129.2% in the 2nd quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock worth $194,000 after buying an additional 1,202 shares during the period. Finally, Cerity Partners LLC grew its holdings in Zimmer Biomet by 93.6% during the 2nd quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock worth $7,004,000 after acquiring an additional 37,116 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.